Early trial success for HeartStent:
This article was originally published in Clinica
HeartStent, a Minneapolis-based company developing a method for revascularising the heart using a device that passes through the heart wall and into the coronary artery, has reported early trial success. Preclinical results of the VCAB (ventriculocoronary artery bypass) procedure are published in the March edition of The Heart Surgery Forum and the company claims the device eliminates the need to harvest vessels for bypass and can be implanted in a beating heart.
You may also be interested in...
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.
The Swiss giant is hoping to get seven more approvals for its blockbuster immunology drug over the next 10 years.
Cadila has filed for approval of saroglitazar for NASH in India. The drug, which could emerge as the first medicine for the indication if approved, is already being used by a million Indian patients for diabetic dyslipidemia and hypertriglyceridemia.